Literature DB >> 8390258

Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase.

A J Kettle1, C A Gedye, C C Winterbourn.   

Abstract

Myeloperoxidase, the most abundant enzyme in neutrophils, catalyses the conversion of hydrogen peroxide and chloride to hypochlorous acid. This potent oxidant has the potential to cause considerable tissue damage in many inflammatory diseases. We have investigated the ability of dapsone, diclofenac, primaquine, sulfapyridine and benzocaine to inhibit hypochlorous acid production by stimulated human neutrophils. The drugs were also tested against purified myeloperoxidase using xanthine oxidase to generate hydrogen peroxide and superoxide. The inhibitory effects of the drugs on hypochlorous acid production, either by cells stimulated with phorbol myristate acetate or by myeloperoxidase and xanthine oxidase, were significantly less than those determined with myeloperoxidase and reagent hydrogen peroxide. Comparable potency was observed only when superoxide dismutase was present to remove superoxide. We also observed that with the xanthine oxidase system, inhibition of hypochlorous acid production by dapsone decreased markedly as the concentration of myeloperoxidase increased. Dapsone was a poor inhibitor of hypochlorous acid production by neutrophils stimulated with opsonized zymosan, regardless of the presence of superoxide dismutase. With this phagocytic stimulus, catalase inhibited hypochlorous acid formation by only 60%, which indicates that a substantial amount of the hypochlorous acid detected originated from within phagosomes. Thus, it is apparent that dapsone is unable to affect intraphagosomal conversion of hydrogen peroxide to hypochlorous acid. All the drugs inhibit myeloperoxidase reversibly by trapping it as its inactive redox intermediate, compound II. We propose that superoxide limits the potency of the drugs by reducing compound II back to the active enzyme. Furthermore, under conditions where the activity of myeloperoxidase exceeds that of the hydrogen peroxide-generating system, which is most likely to occur in phagosomes, partial inhibition of myeloperoxidase need not affect hypochlorous acid production. We conclude that drugs that inhibit myeloperoxidase by converting it to compound II are unlikely to be effective against hypochlorous acid-mediating tissue damage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390258     DOI: 10.1016/0006-2952(93)90010-t

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation.

Authors:  Anna-Karin Tidén; Tove Sjögren; Mats Svensson; Alexandra Bernlind; Revathy Senthilmohan; Francoise Auchère; Henrietta Norman; Per-Olof Markgren; Susanne Gustavsson; Staffan Schmidt; Stefan Lundquist; Louisa V Forbes; Nicholas J Magon; Louise N Paton; Guy N L Jameson; Håkan Eriksson; Anthony J Kettle
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

Review 3.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

4.  Thiocyanate and chloride as competing substrates for myeloperoxidase.

Authors:  C J van Dalen; M W Whitehouse; C C Winterbourn; A J Kettle
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

5.  Oxidation of neutrophil glutathione and protein thiols by myeloperoxidase-derived hypochlorous acid.

Authors:  A C Carr; C C Winterbourn
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

6.  Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide.

Authors:  A J Kettle; C A Gedye; C C Winterbourn
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

Review 7.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

8.  Inhibition of myeloperoxidase-mediated hypochlorous acid production by nitroxides.

Authors:  Martin D Rees; Steven E Bottle; Kathryn E Fairfull-Smith; Ernst Malle; John M Whitelock; Michael J Davies
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

9.  Fucoxanthin in association with vitamin C acts as modulators of human neutrophil function.

Authors:  A C Morandi; N Molina; B A Guerra; A P Bolin; R Otton
Journal:  Eur J Nutr       Date:  2013-09-06       Impact factor: 5.614

Review 10.  Myeloperoxidase: a potential therapeutic target for coronary artery disease.

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Expert Opin Ther Targets       Date:  2020-05-07       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.